Equities analysts expect Acceleron Pharma Inc (NASDAQ:XLRN) to announce ($0.24) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Acceleron Pharma’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.35). Acceleron Pharma posted earnings of ($0.63) per share during the same quarter last year, which indicates a positive year over year growth rate of 61.9%. The business is expected to announce its next earnings report after the market closes on Monday, August 5th.
According to Zacks, analysts expect that Acceleron Pharma will report full-year earnings of ($2.44) per share for the current year, with EPS estimates ranging from ($2.78) to ($1.98). For the next year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.60) to ($1.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). The firm had revenue of $2.78 million during the quarter, compared to analyst estimates of $3.67 million. Acceleron Pharma had a negative return on equity of 35.94% and a negative net margin of 965.39%. The business’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.58) earnings per share.
A number of research firms have weighed in on XLRN. Morgan Stanley set a $53.00 target price on Acceleron Pharma and gave the stock a “hold” rating in a research report on Monday, July 15th. ValuEngine downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. BidaskClub upgraded Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday. Barclays downgraded Acceleron Pharma from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $54.00 to $45.00 in a research report on Friday, May 3rd. Finally, Oppenheimer reiterated an “outperform” rating on shares of Acceleron Pharma in a research report on Monday, April 22nd. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Acceleron Pharma has a consensus rating of “Buy” and a consensus price target of $60.63.
XLRN traded up $0.17 during trading on Friday, reaching $44.04. The stock had a trading volume of 458,033 shares, compared to its average volume of 251,530. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -17.00 and a beta of 1.17. The company has a quick ratio of 19.26, a current ratio of 19.26 and a debt-to-equity ratio of 0.05. Acceleron Pharma has a 1-year low of $37.01 and a 1-year high of $59.59. The stock has a 50 day simple moving average of $41.36.
In related news, Director Joseph S. Zakrzewski acquired 5,000 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was bought at an average price of $38.05 per share, for a total transaction of $190,250.00. Following the transaction, the director now owns 12,750 shares of the company’s stock, valued at $485,137.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jean George sold 25,688 shares of the stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $39.16, for a total value of $1,005,942.08. Following the sale, the director now owns 23,750 shares of the company’s stock, valued at approximately $930,050. The disclosure for this sale can be found here. Insiders have sold a total of 63,726 shares of company stock valued at $2,519,969 in the last quarter. Insiders own 2.50% of the company’s stock.
A number of large investors have recently made changes to their positions in XLRN. FMR LLC increased its stake in shares of Acceleron Pharma by 6.3% in the first quarter. FMR LLC now owns 7,363,953 shares of the biopharmaceutical company’s stock worth $342,939,000 after acquiring an additional 435,414 shares during the last quarter. Norges Bank acquired a new position in shares of Acceleron Pharma in the fourth quarter worth $17,535,000. Marshall Wace North America L.P. increased its stake in shares of Acceleron Pharma by 6,720.3% in the first quarter. Marshall Wace North America L.P. now owns 383,166 shares of the biopharmaceutical company’s stock worth $17,844,000 after acquiring an additional 377,548 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Acceleron Pharma by 132.1% in the fourth quarter. Bank of New York Mellon Corp now owns 439,644 shares of the biopharmaceutical company’s stock worth $19,147,000 after acquiring an additional 250,254 shares during the last quarter. Finally, TimesSquare Capital Management LLC increased its stake in shares of Acceleron Pharma by 29.5% in the first quarter. TimesSquare Capital Management LLC now owns 920,715 shares of the biopharmaceutical company’s stock worth $42,878,000 after acquiring an additional 209,900 shares during the last quarter. 92.55% of the stock is currently owned by institutional investors.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
See Also: Current Ratio
Get a free copy of the Zacks research report on Acceleron Pharma (XLRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.